Tandem Diabetes Care, Inc. financials

TNDM CIK 0001438133

Source: EDGAR filings · Built 2026-06-02T04:11:41Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow -29.67M 4.99M -58.61M 16.37M 97.18M -2.74M
EBITDA -169.59M -82.52M -217.51M -78.52M 36.50M 2.49M
Working Capital 375.42M 477.44M 552.73M 684.69M 679.66M 533.38M
Net Debt 353.84M 404.33M 356.80M 247.36M 243.49M 133.71M
Gross Margin 53.81% 52.07% 49.17% 51.54% 53.53% 52.23%
Operating Margin -18.45% -10.54% -31.19% -11.59% 3.22% -1.60%
Net Margin -20.17% -10.21% -29.77% -11.81% 2.21% -6.89%
Return on Equity (ROE) -131.93% -36.50% -70.98% -21.50% 3.59% -9.39%
Return on Assets (ROA) -23.23% -9.92% -23.37% -8.99% 1.72% -4.80%
Current Ratio 2.55× 2.93× 3.83× 5.14× 6.15× 6.14×
Debt-to-Equity 2.86× 1.80× 1.33× 0.95× 0.73× 0.62×
Effective Tax Rate -2.22% -4.52% -1.07% -1.88% 2.11% 5.24%
Cash Conversion Ratio 0.05× -0.25× 0.14× -0.53× 7.15× -0.72×
Accruals Ratio -0.22× -0.12× -0.20× -0.14× -0.11× -0.08×
SBC % of Revenue 9.10% 10.78% 11.78% 10.60% 8.64% 11.71%
CapEx Coverage -0.49× 1.26× -1.19× 1.48× 7.85× 0.90×
Free Cash Flow Per Share $-0.44 $0.08 $-0.90 $0.26 $1.51 $-0.04

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/E Trailing (Diluted) 627.17×
P/FCF 472.08× 176.14× 99.67×
FCF Yield 0.21% 0.57% 1.00%
EV / EBITDA 269.92× 2445.04×
P/S 1.48× 2.54× 2.59× 3.62× 13.67× 11.96×
P/B 9.67× 9.07× 6.18× 6.59× 22.18× 16.28×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 1.01B 940.20M 747.72M 801.22M 702.80M 498.83M
Cost of Goods and Services Sold 468.72M 450.63M 380.03M 388.23M 326.58M 238.31M
Gross Profit 546.01M 489.57M 367.69M 412.99M 376.21M 260.52M
Research and Development Expense 92.05M 63.57M
Selling, General and Administrative Expense 444.99M 389.82M 352.50M 335.68M 261.51M 204.90M
Operating Expenses 733.27M 588.70M 600.92M 505.83M 353.56M 268.48M
Operating Income (Loss) -187.26M -99.13M -233.23M -92.85M 22.65M -7.96M
Income Tax Expense (Benefit) 4.44M 4.16M 2.36M 1.74M 335.00K -1.90M
Net Income (Loss) Attributable to Parent -204.71M -96.03M -222.61M -94.59M 15.57M -34.38M
Earnings Per Share, Basic $-3.04 $-1.47 $-3.43 $-1.47 $0.25 $-0.56
Weighted Average Number of Shares Outstanding, Basic 67.28M 65.45M 64.97M 64.15M 63.00M 60.99M
Earnings Per Share, Diluted $-3.04 $-1.47 $-3.43 $-1.47 $0.24 $-0.56
Weighted Average Number of Shares Outstanding, Diluted 67.28M 65.45M 64.97M 64.15M 64.35M 60.99M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 90.63M 69.23M 58.87M 172.52M 71.18M 94.61M
Assets, Current 618.14M 724.49M 747.99M 849.98M 811.52M 637.24M
Assets 881.11M 967.66M 952.66M 1.05B 905.14M 716.41M
Liabilities, Current 242.72M 247.05M 195.26M 165.29M 131.86M 103.85M
Long-term Debt, Excluding Current Maturities 310.04M 308.27M 285.04M
Liabilities 725.94M 704.56M 639.03M 612.84M 472.02M 350.11M
Stockholders' Equity Attributable to Parent 155.17M 263.10M 313.63M 439.95M 433.11M 366.31M
Common Stock, Shares, Outstanding 68.29M 66.26M 65.55M 64.51M 63.83M 62.34M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities -9.72M 24.23M -31.81M 50.46M 111.36M 24.67M
Payments to Acquire Property, Plant, and Equipment 19.95M 19.23M 26.80M 34.10M 14.18M 27.41M
Net Cash Provided by (Used in) Investing Activities 72.88M -23.48M -85.74M 33.17M -186.88M -296.06M
Payments for Repurchase of Common Stock 0 30.00M 0 0
Net Cash Provided by (Used in) Financing Activities -43.37M 8.37M 4.11M 16.88M 51.93M 314.44M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (TNDM CIK 0001438133), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

CATY

Cathay General Bancorp

KOD

KODIAK SCIENCES INC.

SNX

TD SYNNEX CORPORATION